Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Place your bets!
Hello.
Bantham.
As I said clearly Mr Newland and the board see the massive potential here for this CellKeep™ slide or they would not have applied for patents in the EU and USA. A simple, by the looks cheap to make plastic device which is far gentler on the cells that end up on the microscope slide. Not only that, but the cells are also concentrated in a smaller area. So, any cells are far less likely to get damaged/killed and are in a smaller area so easier to find! Plus, it says using the device should save on the cost of antibodies as less are needed. Three very positive points for adopting the use of this device! The RNS says the device with the "Portrait Plus CTC staining kit" and Mr Newland says they might offer it separately. Offering it separately would be potentially handing the advantage the device gives their Parsortix machine to some competitors. Having said that competing methods to capture circulating tumour cells are complicated and come with very specific instructions on how to use the particular system. Unlikely to say "then use an Angle Plc CellKeep™ slide” to obtain the cells for viewing with the microscope! I think Angle Plc should immediately offer this device Worldwide through distributors. It could and up as a standard device for use when the cells to be viewed are liable to get damaged during the normal centrifuge process. Sales of potentially tens of thousands world-wide.
https://www.lse.co.uk/rns/AGL/us-and-eu-patents-for-innovative-cellkeep8482-slide-3s3v2c8b8y6u32u.html
All IMHO.
Bantham.
Clearly Mr Newland and the board see the massive potential here for this CellKeep™ slide or they would not have applied for patents in the EU and USA. Having had more a think it could be a very major part of Angles revenues. In fact Worldwide something like this cheap to make plastic "slide" could end up being the biggest money maker for Angle. This device, which obviously is far more gentle on the cells it captures on the slides so they are less damaged, and as the RNS says concentrates the CTCs into a smaller area on the slide (making processing cheaper) could easily become extremely popular............. WORLD WIDE. That is a big market. Sales could in time be in the tens of thousands, or even more.
As ANGLE Chief Scientific Officer, Karen Miller said "This technology is a significant advancement over current standards for CTCs and has the potential to capture other cell types from body fluids such as blood, urine or cerebrospinal fluid, for subsequent analysis".....................................................................................Holy **it.
MUCH more significant than the 4.12% gain today which is a total joke.
All IMHO.
Angle have clearly put a huge amount of effort creating this "Portrait Plus CTC staining kit" which includes the innovative CellKeep™ slide referred to in todays RNS. As Andrew explains the kit standardises the stains used, gives the stains greater shelf life (as they are in the form of a dissolvable tablet) and uses the now patented CellKeep™ slide to reduce circulating tumour cell (CTC) loss !!! As he explains the patented CellKeep™ slide makes the Parsortix system far more efficient compared to using the industry standard way which can damage and kill the CTC's. I don't think it's possible to get a better CTC sample (99% alive and undamaged) for subsequent analysis.
https://www.youtube.com/watch?v=hxu_XmeIpDA
All IMHO.
Like this?
Proactive interview with Andrew Newland highlights the work involved
https://www.youtube.com/watch?v=hxu_XmeIpDA
========================
Also very important about the RNS of 4th Jan "Angle PLC Breakthrough clinical results (5877Y)", see link below.:-
Companies doing Cancer drug trials will NOW want standard blood CtDna analysis ***AND*** Circulating Tumour Cell analysis for even more information on how their extremenly expensive drug trials are doing etc. OF COURSE they will want the maximum information available in order to log for the future and evaluate how their drug is performing!!! The IS A NO BRAINER.
And that is just one of Angle's offerings................................................
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
TwoGood2Die.
Let's discuss given FDA approval for breast cancer testing was granted a while back why global sales of the Parsortix machine hasn't taken off any suggestions?
===================================
How do you know sales of the Parsortix machine @ $50,000 to $70,000 have not taken off. Do we need to add insider trading to the list of illegal things you do? LOL! The results are due. We will see if:-
Companies doing Cancer drug trials NOW want standard blood CtDna analysis ***AND*** Circulating Tumour Cell analysis for even more information on how their extremenly expensive drug trials are doing etc. OF COURSE they will want the maximum information available in order to log for the future and evaluate how their drug is performing!!! The IS A NO BRAINER.
And that is just one of Angle's offerings................................................
TwoGood2Die.
Let's discuss given FDA approval for breast cancer testing was granted a while back why global sales of the Parsortix machine hasn't taken off any suggestions?
===================================
How do you know sales of the Parsortix machine @ $50,000 to $70,000 have not taken off. Do we need to add insider trading to the list of illegal things you do? The bottom line I think you will find is the CtD
You are the one that does not understand. You are childish and spend most of your sad time trying to annoy people.
I believe the main way of finding the efficacy (effectiveness) of a new cancer treatment drug for people with metastasized cancer (cancer that has spread) used to be to examine them, test them and ask them. Also compare this information with the people that were given the placebo.
Molecular analysis Companies like Illumina and Thermo Fisher now enable the testing of DNA fragments that can be found in blood from a simple blood sample. These fragments are naturally shed by every cell in your body, and that includes the cancerous ones. Analysing the cancerous ones is called CtDna analysis (cancerous tumour Dna analysis). Angle Plc have discovered the following. If you do exactly the same test on a circulating tumour cell taken from the same blood sample and compare it to the so called CtDna analysis results you sometimes get a different result that gives even more information about the state of the persons cancer. Important up to date information. Angle hypothesize this gives "critical new information not currently available on how the cancer is progressing and which therapies may be affective". I think any Company embarking on a cancer drug trial involving a metastasized cancer MUST want this vital new information. It is a "no brainer". It would be criminal not to get this vital information when doing a very expensive cancer drug trial. Criminal IMHO.
All IMHO.
Should be a massive winner IMHO. From the RNS dated 4th Jan:-
"ANGLE will start using the clinical results announced today to support the offer of sample-to-answer DNA molecular solutions to pharma services customers using the ****combined CTC-DNA and ctDNA analysis"****.
This will give any cancer drug trial Company ALL THE AVAILABLE INFORMATION about any cancer that has
metastasized (spread). I.e. the DNA analysis of the CtDNA in the general blood (fragments of DNA) combined with the DNA analysis of the Circulating tumour cells (cells that detach from a tumour and can spread a cancer). This sort of information is invaluable to understand how a treatment is performing, or not.
All IMHO.
The standard molecular profiling of general blood CtDna (available now using Illumina/Thermo Fisher tech) **AND** circulating tumour cells (CTC's) from the the same blood sample ***for comparison***! See their RNS dated 4th January "Breakthrough clinical results". As pointed out in the RNS, these results meant that it would be in Illumina's etc.. interests to promote the Parsortix machine alongside their standard general blood CtDNA analysis machines to get the "FULL PICTURE". That is using the general blood CtDna and circulating tumour cell CtDNA comparison approach.
Note analysis of the CTC's gave additional sometimes actionable information about the cancer. Actionable in that the standard molecular profiling of general blood CtDna sometimes ***FAILED**** to indicate targetable DNA that ***WAS FOUND*** IN THE circulating tumour cells! Thus, an opportunity to treat the cancer with targeted DNA with immunotherapy could be MISSED!!! I believe Angle were/are open to some sort of deal with the likes of Illumina/Thermo Fisher. We will find out soon I suspect.
However, I had failed to realise that for use in cancer drug trials Angle Plc THEMSELVES can offer this service! They already use Illumina kit for blood CtDNA analysis. It said so in the RNS of 4th Jan (see below). Obviously, they have loads of Parsortix machines their lab to obtain the circulating tumour cells and they have the tech to do the comparison as set out in the RNS!! This offering will be groundbreaking IMHO!!
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
All IMHO.
Of a cancers status ONLY when BOTH are analysed from the same tube of blood. See RNS dated 4th Jan. This has massive implications for the cancer immunotherapy treatment Companies throughout the World. Angle have pioneered this new approach and are likely to be the ONLY Company in the World to offer this service to Companies carrying out cancer drug trials.............. Soon. Massive potential profits. I bet we get info on this with the results that are due any day.
All IMHO.
You know the one entitled "Breakthrough clinical results"? Comparing the standard blood CtDna analysis currently offered by the likes of Illumina/Thermo Fisher to the analysis of the circulating tumour cells (obtained using Angle's Parsortix machine) from the same tube of blood was interesting, surely? The results indicated in some cases if the circulating tumour cells were not also analysed then important information could be MISSED. I think that is rather important. Do you agree? I don't quite see how you could not agree! Have a think about that one.
"ANGLE has established a CTC harvest and analysis service from our UK-based Clinical Laboratory based in Guildford for customers worldwide. In alignment with company priorities, we plan to rapidly expand our services to include molecular profiling of CTCs and ctDNA using digital PCR and NGS to add to our image-based assays."
TwoGood2Die.
If Angle are doing so badly as you appear to want people to believe then why are they advertising for a purchasing assistant and a Warehouse/Stores operator? Don't tell me...... it's a ruse to improve the sp!! LOL!
Https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0138032
Https://www.clinicaltrials.gov/study/NCT05648240?term=parsortix&rank=7